The global sales of atrial fibrillation device is estimated to be worth USD 4,628.90 million in 2024 and anticipated to reach a value of USD 13,025.4 million by 2034. Sales are projected to rise at a CAGR of 10.9% over the forecast period between 2024 and 2034. The revenue generated by atrial fibrillation device in 2023 was USD 4,173.90 million.
Atrial fibrillation (AFib) devices are medical devices that are utilized in the management of atrial fibrillation, which is condition where in the upper chamber of heart beat at fast pace with chaotic rhythm. These device reduces the risk of stroke and blood clots that are associated with AFib. Atrial fibrillation device can be Laboratory Devices, Ablation Catheters, Diagnostic Catheters, and Access Devices.
Ablation Catheters are expected to dominate the market with the market share of 58.60%. Hospital segment contributed 61.8% share in revenue growth.
Global Atrial Fibrillation Device Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 4,173.9 million |
| Estimated Size, 2024 | USD 4,628.9 million |
| Projected Size, 2034 | USD 13,025.4 million |
| Value-based CAGR (2024 to 2034) | 10.90% |
Atrial fibrillation, or AF, is the most common cardiac arrhythmia that clinicians encounter. Generally, this condition is associated with increased risks of many adverse health outcomes, which include transient ischemic attack, ischemic stroke, systemic embolism, and even death.
In particular populations with pre-existing comorbidities like chronic heart failure, this risk becomes even higher. AF puts a huge burden on morbidity and mortality and hence increases the load on healthcare systems. In the process, early detection of AF with early and appropriate intervention gives hope for attenuating complications.
The atrial fibrillation device market is growing because of increased risk of stroke and other cardiovascular complications. The demographic trend to an increasingly aging population with a heightened awareness of symptoms and choices for treatment has also contributed to the market expansion.
In the United States 3 to 6 million are living with atrial fibrillation and the number is expected to reach 6 to 16 million by 2050. In Europe the number is expected to reach the 14 million mark in 2060. A similar trend is anticipated in Asia with more than 72 million people diagnosed with AF in 2050. This high prevalence created demand for diagnosis and treatment devices.
Non-pharmacological therapies such as catheter ablation and surgical maze procedures are dominating owing to their higher success rate compared to traditional drug therapies. Hospitals or cardiac catheterization labs are the main end-users in solving complex AFib cases using specialized tools.
Leading market players such as Boston Scientific, Medtronic, and AtriCure set a quickening pace through innovation and implementation of advanced minimally invasive solutions for AFib management. Investments are made in technology advancements that will improve the treatment outcomes and quality of life of patients.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table below compares the Compound Annual Growth Rate (CAGR) for the global atrial fibrillation device market from 2023 to 2024 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics. H1 covers January to June, while H2 spans July to December.
| Particular | Value CAGR |
|---|---|
| H1 | 11.8% (2023 to 2033) |
| H2 | 11.4% (2023 to 2033) |
| H1 | 10.9% (2024 to 2034) |
| H2 | 10.4% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 10.9% in the first half and remain relatively moderate at 10.4% in the second half. In the first half (H1) the market witnessed a decrease of 90 BPS and in the second half (H2) also, the market witnessed a decrease of 100 BPS.
Increasing Prevalence of Atrial Fibrillation is Fueling the Market Growth
Atrial fibrillation is the most common cardiac arrhythmia and has increased significantly over the past few years to about 1 in 3 to 5 individuals facing a lifetime risk after the age of 45. This demographic shift, coupled with other factors such as aging populations and alterations in the lifestyle, has increased the worldwide number of those living with AF from 33.5 million in 2010 to 59 million in 2019.
The health burden of AF extends into increased stroke rates, heart failure, and other cardiovascular complications that imply long-term management and treatment. Fueling the growth in AF incidence and thus, demand for diagnostic tools, therapeutic interventions, and management strategies in the AF market.
Ongoing medical developments toward refined catheter ablation methods, novel mapping technologies, and further enhancements in implantable devices such as pacemakers and defibrillators continue to transform the face of AF treatment for the optimization of therapies for better patient outcomes.
While the growing burden of AF presents an opportunity for the market to drive more adequate clinical management of the disease, it is also addressing cost-effective solutions that improve the quality of life and reduce healthcare costs incurred by AF-related complications.
With increased priority on cardiovascular health and patient-centered care across healthcare systems globally, the atrial fibrillation device market grows correspondingly to meet these increasing needs.
Increasing Geriatric Population Contributed To the Growing Demand for Atrial Fibrillation Devices
Atrial fibrillation is one of the most common cardiac arrhythmias, and its prevalence definitely increases with age. For instance, whereas its prevalence stands at a reasonably low 0.3 percent of individuals in the age group of 40 years, it rises significantly to 5-9 percent at 60 to 80 years and further to about 10 percent among those older than 80 years.
Among the major contributing factors for the high prevalence rate of atrial fibrillation in the aged are related natural degenerative changes that occur with the aging heart.
With advanced age, structural changes in the form of fibrosis and stiffening of cardiac tissues are frequent, predisposing individuals to arrhythmias like atrial fibrillation. These affect the electrical conduction pathways of the heart, thus contributing to the creation and perpetuation of atrial fibrillation.
Furthermore, the development of many cardiovascular and systemic diseases is accompanied by progressive aging. These diseases act in synergy to increase the possibilities of developing atrial fibrillation.
CAD can present with myocardial ischemia and scarring, thus promoting electrical instability within this organ, while a history of hypertension can lead to left ventricular hypertrophy and atrial enlargement, which are risk factors of atrial fibrillation.
Thus, with the growing prevalence of atrial fibrillation in the elderly, proper management and treatment methods will be highly needed, hence creating a resultant demand for atrial fibrillation devices in the market.
Technological Advancement in Electrophysiology Offers New Growth Prospect for Market Growth
Novel technologies such as high-power, short-duration RF ablation, optimized cooling at the electrode-tissue interface, and next-generation balloon catheter platforms hosting Cryo Energy, Laser, and RF are making a difference in AF management.
These new developments help improve the efficiency of pulmonary vein isolation (PVI) one of the cornerstones of AF treatment by making lesions that are long-lasting and reflective of good procedural outcomes.
It will allow high-power RF ablation for faster lesion formation with reduced risk of complications and cryoablation to ultra-low temperatures necessary for precise treatment to ensure effective tissue ablation inflicting minimal damage on the surrounding tissues.
These new pulsed electrical field ablation technologies are showing promise because they provide irreversible electroporation of myocardial tissue, hence reducing possible adverse effects and improving the outcome in patients. These technologies are constantly changing due to the incessant search for improved long-term clinical outcomes and quality of life in patients.
Therefore, more and more healthcare providers and cardiac centers worldwide have adopted these advanced EP tools to be better positioned for minimally invasive treatment options in AF management.
High-Cost Restrict Atrial Fibrillation Device Market Growth
AF devices, including those devices that involve ablation systems with catheters, implantable cardiac monitoring systems, and other special devices, are usually associated with huge costs for institutions and healthcare providers.
Acquiring AF devices requires a huge initial investment, testing the healthcare budget in resource-poor settings and care services where cost is a major consideration. These include the costs of buying the devices, regularly maintaining them, upgrading the devices, and training health care personnel.
Moreover, AF devices expenses may not be covered in the policies of reimbursement and healthcare funding models. This may further complicate the adoption of the device. This financial uncertainty may prevent healthcare providers from investing in new technologies despite their clinical benefits. This can challenge the market growth of atrial Fibrillation devices.
Principal Consultant
The global atrial fibrillation device industry recorded a CAGR of 8.6% during the historical period between 2019 and 2023. The growth of atrial fibrillation device industry was positive as it reached a value of USD 4,173.90 million in 2023 from USD 2,662.4 million in 2019.
The requirement of atrial fibrillation devices have been increasing due to the increase in life expectancy. As the healthcare infrastructure have improved and life expectancy has increased in many developed as well as developing countries the population of elderly people have gone up.
Since old population is more susceptible to the cardiac health problem the demand for atrial fibrillation device have also been high among the same age group. Further the adoption of these devices have also been contributed by the growing awareness about their benefit and increased focus on early detection.
While these factor continue the drive the market for atrial fibrillation devices, technological advancement, expansion of potential application and favorable reimbursement policies will be instrumental in shaping the market’s growth trajectory.
Advancement such as high resolution imaging systems and flexible catheters enhances the diagnostic capabilities. The potential of AFib devices for surgical and non-surgical treatment is being realized. Also the supportive government initiative by providing favorable reimbursement policies for AFib procedures will drive the market expansion.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 59.50% in global market. These market leaders are characterized by high production capacity and a wide product portfolio.
These market leaders are distinguished by their developmental efforts to introduce innovative product in the market. They provide a wide range of atrial fibrillation device. Prominent companies within tier 1 include Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, GE Healthcare, and Siemens Healthineers AG etc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market.
These are characterized by a strong presence overseas and strong market knowledge. These market players have good technology and ensure regulatory compliance but may not have advanced technology and wide global reach. Prominent companies in tier 2 include EP Solutions, Teleflex, Merit Medical Systems Inc., and Biomerics etc.
Compared to Tiers 1 and 2, Tier 3 companies have smaller revenue spouts and less influence. Those in Tier 3 has smaller work force and limited presence across the globe. Prominent players in the tier 3 category are AtriCure, Inc., Biotronik SE & Co. KG, Acutus Medical Inc., and Others
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the atrial fibrillation device market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and Middle East and Africa (MEA), is provided.
The United States is anticipated to remain at the forefront in North America. In Asia Pacific, China is projected to witness a CAGR 10.9% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 5.9% |
| Germany | 3.4% |
| France | 5.5% |
| Italy | 5.0% |
| China | 10.9% |
| South Korea | 8.6% |
| Japan | 4.5% |
Germany’s atrial fibrillation device market is poised to exhibit a CAGR of 3.4% between 2024 and 2034. Currently, it holds the highest share in the European market, and the trend is expected to continue during the forecast period.
Atrial fibrillation is the most common cardiac arrhythmia in the country, which affects about 1% (or approximately 800,000 individuals) of the general population and thus an existent and reasonable patient base with a requirement for management and treatment options.
The prevalence of AF detected is known to notably increase with age, mostly in patients aged between 35 to 74 years. It was reported to be 2.5% in a German population. This demographic trend underlines the growing pressures for AF management solutions with the aging of Germany's population and its increased life expectancy.
Moreover, the equal distribution of AF risk factors between both sexes further implies that effective treatment strategies would be required uniformly in both genders. In view of the associated risk of stroke, which is as high as 2.8% to 3.2% per annum in subjects with AF, there is a greater thrust on preventive measures and sophisticated therapeutic interventions.
Technological advancements in atrial fibrillation treatment has increased demand for ablation procedures and new pharmaceutical therapies. Not only do they contribute to better patient outcomes, but they also foster the growth of AF devices in Germany by providing more effective and highly personalized ways of managing the common cardiac condition.
North America, spearheaded by the USA currently holds around 25.0% share of the global atrial fibrillation device industry. North America’s market is anticipated to grow at a CAGR of 3.4% throughout the forecast period.
AI-powered smart watches and smart phones using photoplethysmography, among other wearable devices, have really changed the concept of AF monitoring in mostly asymptomatic populations. The convenience of these advanced technologies, including the photoplethysmography normally found in modern smartwatches and smartphones, is simply unparalleled with real-time monitoring facilitated via the capture of health data.
Different from complex, uncomfortable, ambulatory Holter monitors, which are very difficult to analyze based on the data output, wearable devices offer a friendly approach that motivates carrying on periodic health checks.
Indeed, the shift to wearable AF detection devices further increases access and coverage across the USA population and empowers consumers toward more proactive healthcare management.
Continued adoption by individuals is driving strong growth in wearable health devices. With their ease of use and commonness, such gadgetry is an excellent modality for the detection of AF outside traditional clinical settings, which then begets earlier diagnosis and timely intervention.
Moreover, such devices with AI integrated are capable of interpreting heart rhythms and identifying any abnormality with high accuracy.
Technological advances of such strides support the early identification of AF and help foster an environment among its users where self-monitoring is promoted, thus giving rise to better health outcomes. Such innovative devices are bound to take a lead in future cardiovascular health management because adoption rates continue to soar.
The cardiovascular disease have increased owing to the various factors. At the foremost is the changing lifestyle, which accounts for surge in risk factor such as Tobacco Use, changing dietary habits, sedentary lifestyle, rise in obesity, and stress.
Over the course of past decades there have been increase in the negative implication of the changing lifestyle of cardiac health. These include rising prevalence of hypertension, Dyslipidemia, Diabetes, Chronic Kidney Disease, Metabolic Syndrome etc. As a result of which the cardio vascular diseases have increased including atrial fibrillation.
In the last couple of decades, China has dramatically improved its health infrastructure and increased access to health services. Development of clinical capabilities and greater availability of AF devices in hospitals have greatly facilitated the diffusion process of the devices among health professionals.
The Chinese government has rolled out the "Healthy China 2030" program, which concerns health policies geared toward ensuring cardiovascular health. The policies provide great emphasis on the prevention of diseases and their active promotion in ensuring improved health outcomes through advanced medical technologies, including AF devices.
Hence, the aggregate effect of growing patient awareness and government support will provide an enabling environment for the huge increase in AF device adoption. Hence the join effect of increased patient and government initiatives has provided boom to China Atrial Fibrillation device market.
The section contains information about the leading segments in the industry. By product, ablation catheters segment is estimated to contribute 58.6% market share in 2024. Additionally, the hospitals end user is projected to record 61.8% market share.
| Product | Ablation Catheters |
|---|---|
| Value Share (2024) | 58.6% |
The Ablation Catheters segment dominates the market in terms of revenue, accounting for almost 58.6% of the market share in 2024.
Ablation catheters are central components in the treatment of AFib because they locate and destroy abnormal tissue in the projecting areas of the heart, which project abnormal electric signals. These procedures are very effective, because they offer high success rate at restoring normal heart rhythm.
Therefore, more and more healthcare professionals turn to them in search of treatment with sure results for AFib patients. Generally, ablation procedures are minimally invasive, hence improving recovery time for patients while minimizing their complication risks, which in turn improves general outcome and satisfaction.
Advancement in ablation catheter technology by integration with 3D mapping systems and advanced energy sources, including radiofrequency and cryoablation, further enhances the precision and safety of treatment.
Therefore, these developments do not only mean gains in procedural effectiveness but also a broadening in the application of ablation techniques to a large spectrum of patients and AFib severities.
| Material | Hospitals |
|---|---|
| Value Share (2024) | 61.80% |
Hospitals, offer specialized capabilities, comprehensive treatment infrastructure, and established connections with healthcare. The medical professionals such as cardiologists, electrophysiologists, and cardiac surgeons are highly trained in treating complex cardiac arrhythmias like AFib. Highly experienced medical professionals are needed to diagnose such problems with accuracy and treat them with the best devices.
Besides, hospitals are now deploying modern technologies such as highly advanced mapping systems, ablation catheters, pacemakers, and implantable cardioverter-defibrillators that are mandated to assist patients in intervening at all points in AFib care. These hospitals can provide integrated care from diagnosis to complex interventions and long-term management with continuity and effectiveness.
It is through the established ties with healthcare reimbursement programs that hospitals are advanced financially, as well as getting easier access to funding for services and devices related to AFib.
With this financial support, it becomes possible for the institutions to invest in innovative technologies, increasing the availability of advanced treatments to AFib patients. Since hospital provide comprehensive care they are dominating the atrial fibrillation device market.
Key players operating in the atrial fibrillation device market are focusing on research and development to build innovative solution and get regulatory approval for it. Large established market player are incorporating strategies such as collaboration to increase their market reach. The main cornerstone for the market player is make product that emphasis evidence based clinical practice.
Recent Industry Developments in Atrial Fibrillation Device Market
In terms of product, the industry is divided into laboratory devices (3D mapping systems, EP recording systems, RF ablation systems, ICE systems, cardiac stimulators, and others), ablation catheters (cryoablation, RF ablation, irrigated tip RF, laser), diagnostic catheters (conventional, advanced, and ultrasound), and access devices.
By end user, the industry is bifurcated into hospitals, ambulatory surgical centers, and cardiac catheterization laboratories.
Key countries of North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and Middle East and Africa (MEA), have been covered in the report.
The global atrial fibrillation device industry is projected to witness CAGR of 10.90% between 2024 and 2034.
The global atrial fibrillation device industry stood at USD 4,173.9 million in 2023.
The global atrial fibrillation device industry is anticipated to reach USD 13,025.4 million by 2034 end.
India is set to record the highest CAGR of 12.30% in the assessment period.
The key players operating in the global atrial fibrillation device industry include Biosense Webster, Inc, Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, GE Healthcare, Siemens Healthineers AG, Koninklijke Philips N.V., Japan Lifeline Co. Ltd., Stereotaxis, Inc., Microport Scientific Corporation, AtriCure, Inc., Biotronik SE & Co. KG, Acutus Medical Inc., Baylis Medical Company, Inc., EP Solutions, Teleflex, Merit Medical Systems Inc., and Biomerics.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Product 5.2. By End User 5.3. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Product 6.1. Laboratory Devices 6.1.1. 3D Mapping Systems 6.1.2. EP Recording Systems 6.1.3. RF Ablation Systems 6.1.4. ICE Systems 6.1.5. Cardiac Stimulators 6.1.6. Others 6.2. Ablation Catheters 6.2.1. Cryoablation 6.2.2. RF Ablation 6.2.3. Irrigated Tip RF 6.2.4. Laser 6.3. Diagnostic Catheters 6.3.1. Conventional 6.3.2. Advanced 6.3.3. Ultrasound 6.4. Access Devices 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 7.1. Hospitals 7.2. Ambulatory Surgical Centers 7.3. Cardiac Catheterization Laboratories 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 8.1. North America 8.2. Latin America 8.3. East Asia 8.4. South Asia and Pacific 8.5. Western Europe 8.6. Eastern Europe 8.7. Middle East and Africa 9. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 10. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Sales Forecast 2024 to 2034 by Product, and End User for 30 Countries 17. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 18. Company Profile 18.1. Biosense Webster, Inc 18.2. Abbott Laboratories 18.3. Medtronic Plc 18.4. Boston Scientific Corporation 18.5. GE Healthcare 18.6. Siemens Healthineers AG 18.7. Koninklijke Philips N.V. 18.8. Japan Lifeline Co. Ltd. 18.9. Stereotaxis, Inc. 18.10. Microport Scientific Corporation 18.11. AtriCure, Inc. 18.12. Biotronik SE & Co. KG 18.13. Acutus Medical Inc. 18.14. Baylis Medical Company, Inc. 18.15. EP Solutions 18.16. Teleflex 18.17. Merit Medical Systems Inc. 18.18. Biomerics
Explore Healthcare Insights
View Reports
Atrial Fibrillation Device Market
